| Title |
Value of Galectin-3 in Acute Myocardial Infarction
|
|---|---|
| Published in |
American Journal of Cardiovascular Drugs, November 2019
|
| DOI | 10.1007/s40256-019-00387-9 |
| Pubmed ID | |
| Authors |
Mingxing Li, Yong Yuan, Kai Guo, Yi Lao, Xuansheng Huang, Li Feng |
| Abstract |
Galectins are an ancient family of lectins characterized by evolutionarily conserved amino acid sequences and β-galactoside recognition and binding sites. Galectin-3 (Gal-3) is one of 15 known galectins. This protein has important functions in numerous biological activities, including cardiac fibrosis and heart failure. In recent years, many studies have shown that Gal-3 is closely associated with acute myocardial infarction (AMI) and may be a promising biomarker for the assessment of severity as well as prognosis prediction in AMI patients, but controversy still exists. In this review, we summarize the latest literature on the relationship between Gal-3 and unstable plaques, the secretion kinetics of Gal-3 during the acute phase of AMI, and the value of Gal-3 in the prediction of post-AMI remodeling. Finally, the possible value of Gal-3 as a biological target for AMI therapy is examined. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 23 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 8 | 35% |
| Researcher | 2 | 9% |
| Student > Doctoral Student | 1 | 4% |
| Lecturer | 1 | 4% |
| Student > Master | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 9 | 39% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 48% |
| Biochemistry, Genetics and Molecular Biology | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Unknown | 10 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 December 2019.
All research outputs
#20,592,137
of 23,177,498 outputs
Outputs from American Journal of Cardiovascular Drugs
#401
of 435 outputs
Outputs of similar age
#384,732
of 459,330 outputs
Outputs of similar age from American Journal of Cardiovascular Drugs
#12
of 12 outputs
Altmetric has tracked 23,177,498 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 435 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 459,330 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.